New science is giving hope to the over 800 million adults worldwide living with diabetes, with prevention, early detection, and innovative treatments potentially changing the outlook for both Type 1 ...

In a large real-world analysis across three U.S. healthcare databases, semaglutide and tirzepatide showed cardiovascular benefits consistent with randomized trials. Semaglutide lowered heart attack ...

Researchers developed a model using routine clinical data to identify optimal glucose-lowering therapies for patients with type 2 diabetes (T2D). Individuals receiving model-predicted optimal therapy ...

Three popular GLP-1 receptor agonists carried similar risks for serious gastrointestinal (GI) events among adults with type 2 ...

Trump announced new deals with Eli Lilly and Novo Nordisk to lower GLP-1 costs for Medicare, Medicaid, and cash-paying patients.

People with type 2 diabetes who combined healthy lifestyle habits with GLP-1 receptor agonist (GLP-1 RA) medications had a ...

Scripps Research in La Jolla announce a new clinical trial that will assess the effectiveness of using drugs approved for diabetes treatment and weight loss to treat long COVID-19, the debilitating ...